SCHEMBL989087

SCHEMBL989087

N#Cc1ccc2c(c1)C(C1(c3ccccn3)CCC1)N(C(=O)O)CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 5/20 0.38
CYP3A4 P08684 1/20 0.35
IDO1 P14902 1/20 0.35
TDO2 P48775 1/20 0.35
GRM5 P41594 1/20 0.35
CNR2 P34972 1/20 0.35
ABCC9 O60706 3/20 0.34
DRD2 P14416 3/20 0.34
DRD3 P35462 3/20 0.34
ABCC8 Q09428 2/20 0.34
KCNJ11 Q14654 2/20 0.34
KCNJ8 Q15842 2/20 0.34
KDM1A O60341 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
AKR1C3 P42330 1/20 0.34
LMNA P02545 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8033549 0.88 DRD2 (0.39) HSD11B1GRM5DRD2KDM1A
SCHEMBL989840 0.86 DRD1 (0.37) HSD11B1CNR2DRD2
SCHEMBL989686 0.83 CNR2 (0.35) HSD11B1CNR2DRD2DRD3CYP2D6
SCHEMBL1860675 0.79 HSD11B1 (0.37) HSD11B1DRD2DRD3HRH3
SCHEMBL1862538 0.76 SLC6A9 (0.47) CYP3A4CYP2D6
SCHEMBL12629640 0.75 SLC6A9 (0.43) HSD11B1CYP3A4IDO1TDO2DRD2
Hydrochloric Acid SCHEMBL989881 0.74 SLC6A9 (0.42) HSD11B1CYP3A4IDO1TDO2DRD2
SCHEMBL8027935 0.74 ESR2 (0.42) GRM5KDM1A
Oxalic Acid SCHEMBL7529629 0.74 DRD1 (0.41) DRD2CYP2D6LMNA
SCHEMBL7419935 0.72 DRD1 (0.42) DRD2DRD3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957089-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2015-02-17 US disclosed
US-8653100-B2 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2014-02-18 US disclosed
US-20130203749-A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2013-08-08 US disclosed
EP-2271625-B1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBOTT GMBH & CO KG (DE) 2012-09-12 EP disclosed
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott BmbH & Co. KG (DE) 2011-05-05 US disclosed
EP-2271625-A2 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY Abbott GmbH & Co. KG (DE) 2011-01-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105502-A1 TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY GOLT1B, SLC10A1, SUGT1 HSD11B1 1303/4885CYP3A4 328/4885IDO1 477/4885
US-20130203749-A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy GOLT1B, SLC10A1, SUGT1 HSD11B1 1303/4885CYP3A4 328/4885IDO1 477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.